Updated HIV Drug Guidelines Available on the Internet

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 6
Volume 8
Issue 6

BETHESDA, Md-The newest version of “Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents” is now available on the Internet at www.hivatis.org. The update includes recommendations about the use of Ziagen (abacavir), which can be given in combination with Retrovir (zidovudine) and Epivir (lamivudine). All three drugs are nucleoside analog reverse transcriptase inhibitors.

BETHESDA, Md—The newest version of “Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents” is now available on the Internet at www.hivatis.org. The update includes recommendations about the use of Ziagen (abacavir), which can be given in combination with Retrovir (zidovudine) and Epivir (lamivudine). All three drugs are nucleoside analog reverse transcriptase inhibitors.

However, the panel that created the guidelines is concerned about the ability of this three-drug regimen “to adequately suppress HIV replication in individuals with high baseline levels of plasma viral load,” said co-chair John G. Bartlett, MD, of Johns Hopkins Medical Center. Thus, it recommends the Ziagen-Retrovir-Epivir combination be considered an “alternative” to other regimens described in the guidelines.

The guidelines are a joint effort by the US Department of Health and Human Services and the Henry J. Kaiser Family Foundation.

Recent Videos
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Related Content